Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Status:
Enrolling by invitation
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA
and glutamate, quantified as a CSF-corrected absolute concentration percent change from
baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale
(MADRS) total score of <10, to the anti-glutamatergic antidepressant ketamine.
As MRS is expensive, we also aim to study a correlation between change in peripheral
metabolites (GABA and glutamate) and central GABA and glutamate levels.